Glaxo Gets FDA Warning Letter

The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.



WASHINGTON — The Food and Drug Administration is stepping up action against GlaxoSmithKline PLC over improper marketing of its popular diabetes drug Avandia, Thursday’s Wall Street Journal reported.

In a formal warning letter dated July 17, the FDA said it had learned that the company’s sales representatives, speaking with doctors at a recent medical conference, denied the existence of serious side effects Avandia users may experience.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in